

TRIUMF INC.

Financial Statements
March 31, 2024



Independent auditor's report

To the Governors of TRIUMF INC.

Our opinion

In our opinion, the accompanying financial statements of TRIUMF INC. (the Entity) as at March 31, 2024 and for the year then ended are prepared, in all material respects, in accordance with the basis of accounting described in note 2 to the financial statements.

What we have audited

The Entity's financial statements comprise:

- the statement of financial position as at March 31, 2024;
- the statement of combined funding and expenditures and changes in fund balances for the year then ended;
- the statement of cash flows for the year then ended; and
- the notes to the financial statements, which include significant accounting policies and other explanatory information.

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements.

Emphasis of matter – basis of accounting and restriction on use

We draw attention to note 2 to the financial statements, which describes the basis of accounting. The financial statements are prepared to assist the Entity in presenting the financial results of the Entity in accordance with the basis of accounting as agreed by the Governors. As a result, the financial statements may not be suitable for another purpose. Our report is intended solely for the Entity. We neither assume nor accept any responsibility or liability to any third party in respect of this report. Our opinion is not modified in respect of this matter.

PricewaterhouseCoopers LLP
PwC Place, 250 Howe Street, Suite 1400, Vancouver, British Columbia, Canada V6C 3S7
T.: +1 604 806 7000, F.: +1 604 806 7806, Fax to mail: ca_vancouver_main_fax@pwc.com



Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation of the financial statements in accordance with the basis of accounting described in note 2 to the financial statements; this includes determining that the applicable financial reporting framework is acceptable for the preparation of the financial statements in the circumstances, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Entity to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

PricewaterhouseCoopers LLP

Chartered Professional Accountants

Vancouver, British Columbia
September 18, 2024

TRIUMF INC.
Statement of Financial Position
As at March 31, 2024


	2024 \$	2023 \$
Assets		
Cash and cash equivalents	17,182,515	8,731,223
Investments (note 3)	17,478,920	16,696,659
Restricted investments (note 4)	13,318,225	12,495,075
Due from Member Universities (notes 6 and 12)	4,233,590	4,802,272
Accounts receivable and other assets (note 5)	5,880,823	11,030,115
	<u>58,094,073</u>	<u>53,755,344</u>
Liabilities		
Accounts payable and accrued liabilities	4,072,734	4,812,537
Funds received in advance (note 7)	7,091,029	6,453,858
	<u>11,163,763</u>	<u>11,266,395</u>
Net Assets		
Externally restricted		
National Research Council Fund	579,182	2,492,005
CERN Cryomodules Fund	1,994,853	1,600,494
Natural Sciences and Engineering Research Council Fund	3,299,640	4,103,473
Institute for Advanced Medical Isotopes	12,638,497	2,722,903
BWXT Medical Fund	100,000	100,000
Decommissioning Fund	13,318,225	12,495,075
	<u>31,930,397</u>	<u>23,513,950</u>
Unrestricted		
Commercial Revenue Fund	10,903,872	13,672,483
Intramural Accounts Fund	4,096,029	3,667,455
	<u>14,999,901</u>	<u>17,339,938</u>
General Fund	12	1,635,061
	<u>46,930,310</u>	<u>42,488,949</u>
	<u>58,094,073</u>	<u>53,755,344</u>

Commitments (note 8)


Economic dependence (note 11)

Subsequent events (note 15)

Approved by the Board of Governors



Director



Director

The accompanying notes are an integral part of these financial statements.

TRIUMF INC.

Statement of Combined Funding and Expenditures and Changes in Fund Balances For the year ended March 31, 2024

	Externally Restricted Fund	Unrestricted Fund	General Fund	2024 \$	2023 \$
Funding/income					
Government grants and contributions	80,850,737	-	-	80,850,737	72,633,884
Advances and reimbursements	9,435,934	677,709	-	10,113,643	9,402,269
Government grants and contributions (NSERC)	6,061,700	-	-	6,061,700	5,509,310
Sub-grant (NSERC)	1,981,390	-	-	1,981,390	1,458,932
Royalties	-	3,467,141	-	3,467,141	3,128,772
Other commercial revenue	-	1,514,373	-	1,514,373	5,467,412
Other revenue	-	1,695,112	159,647	1,854,759	1,977,915
Salaries and benefits recoveries	-	497,469	-	497,469	405,650
Investment income	823,150	-	1,642,311	2,465,461	1,170,476
	<u>99,152,911</u>	<u>7,851,804</u>	<u>1,801,958</u>	<u>108,806,673</u>	<u>101,154,620</u>
Expenditures					
Building and improvement	3,197,295	103,691	82,330	3,383,316	5,228,328
Computer and technology	2,656,829	68,930	33,869	2,759,628	2,790,094
Consulting	2,764,377	1,381,829	338,444	4,484,650	4,381,319
Equipment	13,922,414	932,657	258,089	15,113,160	14,537,025
Power	3,966,076	1,063	-	3,967,139	3,925,013
Salaries and benefits	55,112,055	3,461,269	5,660,992	64,234,316	58,897,808
Supplies and other expenses	7,240,396	817,140	274,833	8,332,369	7,741,663
Telecommunication	82,047	4,892	38,907	125,846	73,372
Travel	1,794,978	93,438	76,474	1,964,890	1,781,241
	<u>90,736,467</u>	<u>6,864,909</u>	<u>6,763,938</u>	<u>104,365,314</u>	<u>99,355,863</u>
Surplus of funding over expenditures for the year	8,416,444	986,895	(4,961,980)	4,441,359	1,798,757
Contribution (to) from other funds	-	(3,326,931)	3,326,931	-	-
Fund balance – Beginning of year	<u>23,513,950</u>	<u>17,339,938</u>	<u>1,635,061</u>	<u>42,488,949</u>	<u>40,690,192</u>
Fund balance – End of year	<u>31,930,394</u>	<u>14,999,902</u>	<u>12</u>	<u>46,930,308</u>	<u>42,488,949</u>

The accompanying notes are an integral part of these financial statements.

TRIUMF INC.

Statement of Cash Flows

For the year ended March 31, 2024

	2024 \$	2023 \$
Cash provided by (used in)		
Operating activities		
Surplus of funding over expenditures for the year	4,441,359	1,798,757
Changes in non-cash working capital items		
Due from Member Universities	568,682	(2,912,566)
Accounts receivable and other assets	5,149,290	(4,269,031)
Accounts payable and accrued liabilities	(739,800)	(2,095,142)
Funds received in advance	637,172	3,023,108
	<hr/>	<hr/>
Changes in fair value of restricted cash and investments	10,056,703 (823,150)	(4,454,874) (216,351)
	<hr/>	<hr/>
	9,233,553	(4,671,225)
Investing activities		
Increase in investments	<hr/> (782,261)	<hr/> (392,098)
Increase (decrease) in cash and cash equivalents during the year	8,451,292	(5,063,323)
Cash and cash equivalents – Beginning of year	<hr/> 8,731,223	<hr/> 13,794,546
Cash and cash equivalents – End of year	<hr/> 17,182,515	<hr/> 8,731,223

The accompanying notes are an integral part of these financial statements.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

1 Nature of operations

TRIUMF INC. (TRIUMF) is Canada's national particle accelerator laboratory. It is owned and operated by a consortium of Canadian universities via a contribution through the National Research Council of Canada (NRC).

On July 1, 2022, TRIUMF amalgamated with TRIUMF Accelerators Inc. (TAI), a not-for-profit federal corporation incorporated in 2006 and controlled by TRIUMF. The assets, liabilities and future obligations of TAI, valued at \$nil, were transferred to TRIUMF. The TRIUMF facility's operating licence that was held by TAI was assumed by TRIUMF, as approval was granted by the CNSC. Additionally, TRIUMF secured a ten-year renewal of its operating licence through to June 30, 2032. As a registered charity, TRIUMF is not subject to income taxes under paragraph 149 (1)(f) of the Income Tax Act (Canada).

As at March 31, 2024, the members of TRIUMF are the University of British Columbia, Simon Fraser University, University of Victoria, University of Alberta, University of Calgary, University of Regina, University of Manitoba, Carleton University, University of Guelph, Queen's University, University of Toronto, York University, McMaster University, McGill University, University of Northern British Columbia, Saint Mary's University, University of Waterloo, Western University, University of Winnipeg, l'Université de Sherbrooke and l'Université de Montréal.

These financial statements include only the assets, liabilities, funding and expenditures of the activities carried on under the control of TRIUMF and do not include the assets, liabilities, revenue and expenditures of the individual member universities.

Sources of funding include grants and contributions from the National Research Council, the Natural Sciences and Engineering Research Council, Canada Foundation for Innovation, Province of British Columbia (Ministry of Health); advances and reimbursements from other sources; commercial revenue; and investment income. TRIUMF has established a number of separate funds to account for the various funding sources. The sources and purposes of these funds are as follows.

National Research Council Fund (NRC)

Funding of operations, improvements and development; expansion of technical facilities (buildings excluded); and general support for experiments.

Natural Sciences and Engineering Research Council Fund (NSERC)

Funding to grantees for experiments related to TRIUMF activities. These funds are administered by TRIUMF on behalf of the grantees.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

Canada Foundation for Innovation (CFI)

Funding to Canadian universities for capital projects related to TRIUMF initiatives and temporary operating funds for newly built infrastructure. These funds are administered by the universities and TRIUMF is reimbursed for expenditures undertaken in accordance with the terms of each grant. The funding that is reported under CFI includes any provincial and third party matching funds required by the grant.

Western Economic Diversification Fund (WD)

Funding for projects related to TRIUMF activities that enhance and strengthen the economy of Western Canada.

Institute for Advanced Medical Isotopes Fund (IAMI)

Funding for the capital construction and operation of a specialized infrastructure to support the expansion of TRIUMF's innovative world-class life sciences program. The funding is derived from federal, provincial and third party sources.

BWXT Medical Fund

Advances and reimbursements from the BWXT Medical Fund for expenditures incurred at TRIUMF.

TRIUMF Innovations Fund

Advances and reimbursements from TRIUMF Innovations Inc. (TI) for expenditures processed by TRIUMF.

Decommissioning Fund

While there is no intention of decommissioning the TRIUMF facilities, the TRIUMF member universities have complied with federal legislation by putting in place a decommissioning plan, including a funding plan, in the event TRIUMF is decommissioned. The decommissioning plan is updated regularly in compliance with TRIUMF's licencing requirements.

Consistent with TRIUMF's accounting policies (note 2), all decommissioning costs will be expensed in the period in which the costs are incurred.

As at March 31, 2024, the balance in the fund, \$13,318,225, is held in an escrow account to fund decommissioning costs. The holdings are invested in cash and mutual funds of \$12.3 million (2023 – \$10.8 million), and equity investments of \$995,102 (2023 – \$1.7 million). The funds are managed by an appointed escrow agent, Royal Trust Corporation of Canada, as agreed to by the Canadian Nuclear Safety Commission (CNSC), a joint venture of each member university and TRIUMF Accelerators Inc. (holder of TRIUMF's operating licence). Each member university has entered into an agreement confirming it will share the cost of any funding shortfall in the event decommissioning costs exceed funding available for decommissioning.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

Affiliated Institutions Fund

Advances and reimbursements for expenditures undertaken on behalf of various Canadian and international institutions for scientific projects and experiments carried out at TRIUMF.

Commercial Revenue Fund

Royalties, revenue and expenditures relating to commercial activities and technology transfer.

Intramural Accounts Fund

Net recoveries generated by internal projects and services. The recoveries of expenditures are charged to the appropriate TRIUMF funding source by the appropriate internal project accounts.

Project Initiatives Fund

Funding for capital and project expenditures that are non-reimbursable, including ineligible expenditures associated with TRIUMF initiatives.

CERN Cryomodules Fund

Funding for the collaboration between the European Organization for Nuclear Research (CERN) and TRIUMF, on the High-Luminosity LHC and construction of RFD Crab Cavities cryomodules.

General Fund

Investment income generated that is used for non-qualifying discretionary expenditures incurred by TRIUMF.

2 Significant accounting policies

Basis of presentation

These financial statements have been prepared in accordance with Canadian public sector accounting standards (PSAS), including accounting standards that apply to government not-for-profit organizations, except that all property, plant and equipment purchased or constructed for use at TRIUMF and related decommissioning costs (if any) are expensed in the year in which the costs are incurred.

TRIUMF has elected not to consolidate its controlled subsidiary, TI. These financial statements do not include the assets, liabilities and results of operations of TI, but rather include the required note disclosures as per note 11.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

Revenue recognition

a) Accounting for contributions

TRIUMF follows the restricted fund method of accounting. Restricted funds include the NRC Fund, the NSERC Fund, the CFI Fund, the WD Fund, the IAMI Fund, the Decommissioning Fund, the BWXT Medical Fund, the TRIUMF Innovations Fund, the CERN Cryomodules Fund and the Affiliated Institutions Fund. Contributions are recognized as revenue in the appropriate fund in the period in which they are received or receivable. Unrestricted contributions are recognized when receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

b) Other revenue

Revenue received in advance for the Affiliated Institutions Fund is deferred as a liability on the statement of financial position and recognized as revenue in the period the related services or expenses are incurred.

Commercial revenue is considered to be realized or realizable and earned when all of the following criteria are met: persuasive evidence of a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectibility is reasonably assured. These criteria are generally met when services are rendered or at the time of product shipment when the risk of loss and title passes to the customer or distributor.

Operating costs

Operating supplies are expensed in the period they are acquired.

Financial instruments

Financial instruments consist of cash and cash equivalents, investments, restricted cash and investments, due from Member Universities, accounts receivable and other assets, accounts payable and accrued liabilities and funds received in advance.

Cash and cash equivalents, investments, restricted cash and investments (other than the holding in mutual funds and equity funds), due from Member Universities, funding receivable, accounts payable and accrued liabilities and funds received in advance are initially measured at fair value and subsequently carried at amortized cost. Investments that are held in mutual funds and equity funds are initially measured and subsequently carried at fair value.

Cash and cash equivalents

Cash and cash equivalents consist of cash on deposit and highly liquid short-term investments with a maturity of less than three months that are readily convertible to a known amount of cash.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

Investments

Investments consist of guaranteed investment certificates that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. Interest earned is recognized as income in the General Fund.

Use of estimates

The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the financial statements and the reported amounts of revenue and expenditures during the reporting period. Actual results could differ from those estimates.

Foreign currency

Foreign currency denominated monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing as at the statement of financial position date, and revenue and expenses expressed in foreign currencies are translated at the rate of exchange prevailing on the date of the transaction. Foreign exchange gains and losses are included in the results of the General Fund.

New accounting standards adopted

Effective April 1, 2023, TRIUMF adopted sections PS 3400 – Revenue, PSG-8 – Purchased Intangibles and PS 3160 – Public Private Partnerships issued by the Public Sector Accounting Board. The adoption of these standards did not have a material impact to these financial statements.

3 Investments

	2024 \$	2023 \$
Fixed income investments	17,478,920	16,696,659

TRIUMF's investments consist of fixed income instruments bearing interest at interest rates ranging from 4.65% to 5.00% with maturities ranging from one to 25 months.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

4 Restricted investments

	2024 \$	2023 \$
Cash	193,939	372,795
Saving accounts	7,069,030	7,359,030
Mutual funds	5,060,154	3,895,974
Equity funds	995,102	867,276
	<u>13,318,225</u>	<u>12,495,075</u>

As at March 31, 2024, carrying value of the mutual funds was \$4,993,921 (2023 – \$3,951,492), carrying value of the equity funds was \$731,446 (2023 – \$704,759).

5 Accounts receivable and other assets

	2024 \$	2023 \$
Commercial revenue	494,524	3,625,546
Funding from government of British Columbia	1,777,621	3,305,000
Recoveries	2,303,097	2,280,280
Prepayments to suppliers	1,006,815	1,664,485
Others	298,766	154,804
	<u>5,880,823</u>	<u>11,030,115</u>

Recoveries primarily include \$984,005 (2023 – \$1,555,288) from BWXT Medical Fund and \$790,244 (2023 – \$468,070) from Affiliated Institutions Fund.

6 Due from Member Universities

	2024 \$	2023 \$
University of Victoria	2,321,092	3,826,082
Simon Fraser University	615,735	499,394
University of British Columbia	1,172,856	406,688
Saint Mary's University	-	37,144
University of Winnipeg	118,709	27,766
University of Alberta	5,198	5,198
	<u>4,233,590</u>	<u>4,802,272</u>

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

7 Funds received in advance

	2024 \$	2023 \$
Externally restricted	6,982,372	6,373,586
Unrestricted	108,657	80,272
	<u>7,091,029</u>	<u>6,453,858</u>

8 Commitments

In addition to the accounts payable and accrued liabilities reflected on the statement of financial position, outstanding commitments, representing the estimated costs of purchase commitments and contracts in place at the fiscal year-end, comprise:

	2024 \$	2023 \$
Building and improvements	150,783	64,695
Computer and technology	1,549,729	2,131,284
Consulting	1,332,841	1,968,358
Equipment and furniture	86,836	3,773,974
Marketing	2,257	-
Safety and insurance	181,811	-
Supplies and other expenses	-	222,088
Telecommunications	20,407	40,814
Travel	-	50,983
	<u>3,324,664</u>	<u>8,252,196</u>

Commitments for the next five years are as follows:

	2025 \$	2026 \$	2027 \$	2028 \$	2029 \$	Total \$
Building and improvements	150,783	-	-	-	-	150,783
Computer and technology	782,464	672,832	53,742	36,103	4,589	1,549,730
Consulting	1,294,175	38,666	-	-	-	1,332,841
Equipment and furniture	42,780	44,056	-	-	-	86,836
Marketing	2,257	-	-	-	-	2,257
Safety and insurance	45,452	45,453	45,453	45,453	-	181,811
Telecommunications	20,406	-	-	-	-	20,406
	<u>2,338,317</u>	<u>801,007</u>	<u>99,195</u>	<u>81,556</u>	<u>4,589</u>	<u>3,324,664</u>

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

9 Financial instruments and risk management

TRIUMF is exposed to a variety of financial risks as disclosed below. TRIUMF is not significantly exposed to market risk or other price risk.

Credit risk

TRIUMF is exposed to credit risk with its cash and cash equivalents and in the event of non-payment by funding agencies or Member Universities. TRIUMF's cash is held with Canadian chartered banks and as the majority of TRIUMF's funding is from the Government of Canada through the NRC and other federal and provincial government agencies for approved projects, this exposure is mitigated.

As at March 31, 2024, the following receivables were past due but not impaired:

	30 days \$	60 days \$	90 days \$	Over 90 days \$
Due from Member Universities	3,378,315	-	532,171	323,104
Funding receivable and other assets	3,452,266	230,974	256,364	505,127

As at March 31, 2023, the following receivables were past due but not impaired:

	30 days \$	60 days \$	90 days \$	Over 90 days \$
Due from Member Universities	2,666,070	1,046,927	154,740	934,535
Accounts receivable and other assets	8,579,538	217,236	55,187	365,037

Interest rate risk

Interest rate risk arises from fluctuations in interest rates and the degree of volatility of these rates. TRIUMF is exposed to interest rate risk on its fixed income instruments. TRIUMF invests in a diversified portfolio of fixed income securities to provide stability of capital within a suitable risk reward framework.

Liquidity risk

Liquidity risk is the risk that TRIUMF will not be able to meet its financial obligations as they come due. TRIUMF's approach to managing liquidity risk is to ensure that it will have sufficient working capital and cash flows to fund operations and settle liabilities when due. All TRIUMF's accounts payable and accrued liabilities are due to be settled in six months or less.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

10 Pension arrangements

The employees of TRIUMF are members of the pension plans sponsored by the University of British Columbia. TRIUMF records the pension expense as cash contributions are made to the plans based on a prescribed percentage of employee earnings. The pension expense for the year was \$4.4 million (2023 – \$3.9 million). In the event there is a future deficiency in the pension plans, the plans' policy for balancing benefits and funding requires a reduction in benefits, starting with future indexing. Consequently, TRIUMF is not required to fund any such deficiency.

11 Economic dependence

TRIUMF's operations are funded under a contribution from the Government of Canada through the NRC. TRIUMF is economically dependent upon this funding source for its ongoing viability. The Government of Canada funded through NRC to TRIUMF with \$292.7 million over the five years from April 1, 2020 to March 31, 2025. On April 16, 2024, the Government of Canada announced in its Budget 2024 that it would provide TRIUMF with \$399.8 million over the next five-year period from April 1, 2025 to March 31, 2030.

12 Related party transactions

TRIUMF enters into transactions with the members of the corporation in the normal course of operations. The members of the corporation are considered related parties to TRIUMF. Amounts due from Member Universities are disclosed in note 6. Revenue from Member Universities is recorded in the CFI Fund and NSERC Fund for subgrants. Salaries and benefits are paid by the University of British Columbia and TRIUMF's paymaster, and are recorded in the applicable funds.

Under the terms of the Membership agreement, the University of British Columbia provides the land and buildings occupied by TRIUMF for \$100 per year to the members. TRIUMF pays for all other goods and services provided by the University of British Columbia and the other Member Universities on a fee-for-service basis.

Balances with related parties are unsecured, non-interest bearing and are due in the normal course of business.

TRIUMF INC.

Notes to Financial Statements

March 31, 2024

13 TRIUMF Innovations Inc. (TI)

As at April 1, 2016, TI became a controlled entity of TRIUMF due to the operational funding support it receives from TRIUMF. During the year ended March 31, 2024, TRIUMF transferred \$1.2 million to TI (2023 – \$1.1 million).

The net assets, revenue and expenses of TI are not consolidated in TRIUMF's financial statements. The financial summary of TI as at March 31, 2024 and 2023 is as follows:

	2024 \$	2023 \$
Financial position		
Total assets	7,337,319	1,010,514
Revenue and expenses		
Revenue	1,334,656	1,412,332
Expenses	(1,071,354)	(1,067,426)
	263,302	344,906
Cash flows		
Cash flows from operating activities	6,369,706	145,358

14 Endowment Fund

A permanent Endowment Fund has been established with the Vancouver Foundation, whereby \$350,000 from TRIUMF was transferred to the Vancouver Foundation during the year ended March 31, 2018. A further \$25,000 was transferred during the year ended March 31, 2022. The capital of the fund is held permanently by the Vancouver Foundation and accordingly is not recorded on the statement of financial position. As at March 31, 2024, TRIUMF received income of \$18,738 (2023 – \$21,371) from the Endowment Fund and recorded it in the Intramural Accounts Fund.

15 Subsequent events

In April 2024, Artms Inc., an entity related to TRIUMF, entered into a purchase agreement with Telix Pharmaceuticals Limited and was acquired effective April 11, 2024.

TRIUMF INC.

Schedule of Funding and Expenditures and Changes in Fund Balance

Externally Restricted Funds

For the year ended March 31, 2024

	National Research Council Fund \$	CERN Cryomodules Fund \$	National Sciences and Engineering Research Council Fund \$	Institute for Advanced Medical Isotopes Fund \$	Canada Foundation for Innovations \$	Affiliated Institutions Fund \$	BWXT Medical Fund \$	Decommissioning Fund \$	2024 \$	2023 \$
Funding/income										
Government grants and contributions	56,900,000	3,200,000	-	13,735,852	7,014,885	-	-	-	80,850,737	72,633,884
Advances and reimbursements	-	-	-	-	-	3,069,783	6,366,151	-	9,435,934	8,769,269
Government grants and contributions (NSERC)	-	-	6,061,700	-	-	-	-	-	6,061,700	5,509,310
Sub-Grants (NSERC)	-	-	1,981,390	-	-	-	-	-	1,981,390	1,458,932
Investment income	-	-	-	-	-	-	-	823,150	823,150	216,351
	<u>56,900,000</u>	<u>3,200,000</u>	<u>8,043,090</u>	<u>13,735,852</u>	<u>7,014,885</u>	<u>3,069,783</u>	<u>6,366,151</u>	<u>823,150</u>	<u>99,152,911</u>	<u>88,587,746</u>
Expenditures										
Building and improvement	473,844	763,995	189	1,198,300	377,947	-	383,020	-	3,197,295	4,707,212
Computer and technology	2,233,851	34,387	125,377	4,059	17,494	211,079	30,582	-	2,656,829	2,524,412
Consulting	1,469,260	-	41,355	853,503	143,552	228,733	27,974	-	2,764,377	2,381,349
Equipment	4,176,601	1,745,049	1,026,390	1,346,492	4,419,257	156,195	1,052,429	-	13,922,413	12,940,916
Power	3,584,577	-	-	65,216	-	-	316,283	-	3,966,076	3,897,544
Salaries and benefits	42,029,821	158,741	5,745,413	208,821	1,440,345	1,622,001	3,906,914	-	55,112,056	55,431,509
Supplies and other expenses	4,249,157	81,615	845,970	142,516	594,155	700,889	626,094	-	7,240,396	6,276,251
Telecommunication	79,986	-	1,514	-	-	547	-	-	82,047	62,660
Travel	515,727	21,854	1,060,717	1,351	22,135	150,339	22,855	-	1,794,978	1,645,900
	<u>58,812,824</u>	<u>2,805,641</u>	<u>8,846,925</u>	<u>3,820,258</u>	<u>7,014,885</u>	<u>3,069,783</u>	<u>6,366,151</u>	<u>-</u>	<u>90,736,467</u>	<u>89,867,753</u>
Surplus (deficit) of funding over expenditures for the year	(1,912,824)	394,359	(803,835)	9,915,594	-	-	-	823,150	8,416,444	(1,280,007)
Fund balance – Beginning of year	<u>2,492,005</u>	<u>1,600,494</u>	<u>4,103,474</u>	<u>2,722,903</u>	<u>-</u>	<u>-</u>	<u>100,000</u>	<u>12,495,074</u>	<u>23,513,950</u>	<u>24,793,957</u>
Fund balance – End of year	<u>579,181</u>	<u>1,994,853</u>	<u>3,299,639</u>	<u>12,638,497</u>	<u>-</u>	<u>-</u>	<u>100,000</u>	<u>13,318,224</u>	<u>31,930,394</u>	<u>23,513,950</u>

TRIUMF INC.

Schedule of Funding and Expenditures and Changes in Fund Balance

Unrestricted Funds

For the year ended March 31, 2024

	TRIUMF Innovations Fund \$	Commercial Revenues Fund \$	Intramural Fund \$	2024 \$	2023 \$
Funding/income					
Advances and reimbursements	677,709	-	-	677,709	633,000
Royalties	-	3,467,141	-	3,467,141	3,128,772
Other commercial revenue	-	1,514,373	-	1,514,373	5,467,412
Other revenue	-	-	1,695,112	1,695,112	1,603,878
Salaries and benefits recoveries	-	-	497,469	497,469	405,650
	677,709	4,981,514	2,192,581	7,851,804	11,238,712
Expenditures					
Building and improvement	-	5,682	98,009	103,691	149,518
Computer and technology	5,999	15,517	47,414	68,930	195,367
Consulting	-	1,369,558	12,271	1,381,829	1,813,978
Equipment	-	835,228	97,429	932,657	1,116,322
Power	-	-	1,063	1,063	27,469
Salaries and benefits	638,159	1,892,417	930,692	3,461,268	3,428,588
Supplies and other expenses	33,551	239,070	544,519	817,140	1,111,815
Telecommunication	-	-	4,892	4,892	9,693
Travel	-	65,722	27,717	93,439	103,274
	677,709	4,423,194	1,764,006	6,864,909	7,956,024
Surplus of funding over expenditures for the year	-	558,320	428,575	986,895	3,282,688
Contribution to other funds	-	(3,326,931)	-	(3,326,931)	-
Fund balance – Beginning of year	-	13,672,483	3,667,455	17,339,938	14,057,250
Fund balance – End of year	-	10,903,872	4,096,030	14,999,902	17,339,938

TRIUMF INC.

Schedule of Funding and Expenditures and Changes in Fund Balance

General Funds

For the year ended March 31, 2024

	2024 \$	2023 \$
Funding/income		
Other revenue	159,647	374,037
Investment income	1,642,311	954,125
	<hr/> 1,801,958	<hr/> 1,328,162
Expenditures		
Building and improvement	82,330	371,598
Computer and technology	33,869	70,315
Consulting	338,444	185,992
Equipment	258,089	479,787
Salaries and benefits	5,660,992	37,711
Supplies and other expenses	274,833	353,597
Telecommunication	38,907	1,019
Travel	76,474	32,067
	<hr/> 6,763,938	<hr/> 1,532,086
Deficit of funding over expenditures for the year	(4,961,980)	(203,924)
Contribution to other funds	3,326,931	-
Fund balance – Beginning of year	1,635,061	1,838,985
Fund balance – End of year	<hr/> 12	<hr/> 1,635,061